Athersys (ATHX) – Business Wire
-
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
-
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
-
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
-
Athersys Licenses its Animal Health Assets to Ardent Animal Health
-
Athersys Director Jane Wasman Appointed Board Chair
-
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
-
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
-
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
-
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
-
Athersys to Host Business Update Conference Call on August 9th
-
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
-
Athersys Restructures Debt with Supplier
-
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
-
Athersys to Participate in Three Upcoming Conferences
-
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
-
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
-
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
-
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
-
Athersys to Host Business Update Conference Call on April 20th
-
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Athersys Announces Successful Type B Meeting with the FDA
-
Athersys Expands IP Protection with First New Patent for SIFU® Technology
-
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
-
Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension
-
Athersys to Host Business Update Conference Call on February 14th
-
Athersys to Participate in International Stroke Conference and BioProcess International
-
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
-
Athersys Provides MultiStem Clinical Update
-
Athersys Appoints Joseph Nolan to Its Board of Directors
-
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
-
Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
-
Athersys Reschedules Third Quarter Conference Call to November 15
-
Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
-
Athersys, Inc. Announces Proposed Public Offering
-
Athersys to Host Third Quarter Financial Results Call
-
Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October
-
Athersys to Host Business Update Conference Call on October 6th
-
Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
-
Athersys Announces 1-for-25 Reverse Stock Split
-
Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
-
Athersys, Inc. Announces $12 Million Registered Direct Offering
-
Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Acros
-
Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
-
Athersys to Host Second Quarter Financial Results Call
-
Athersys and Aspire Capital Fund Terminate Relationship
-
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
-
Athersys Postpones Annual Meeting of Stockholders
-
Athersys Hosting KOL Panel Event to Discuss TREASURE Data
Back to ATHX Stock Lookup
